Cowa LLC Buys Shares of 282 Eli Lilly and Company $LLY
Cowa LLC acquired 282 shares of Eli Lilly, valued at $220,000. Analysts have issued various ratings, with a consensus target price of $1,027.95. Eli Lilly's stock opened at $1,058.05, with a 12-month high of $1,066.65. The company reported quarterly earnings of $7.02 per share, surpassing estimates, and revenue of $17.60 billion, up 53.9% year-over-year.
Cowa LLC acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 282 shares of the company's stock, valued at approximately $220,000.
- A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves
Several other hedge funds also recently bought and sold shares of LLY. Braun Bostich & Associates Inc. increased its holdings in Eli Lilly and Company by 2.5% in the second quarter. Braun Bostich & Associates Inc. now owns 527 shares of the company's stock worth $411,000 after buying an additional 13 shares during the last quarter. Rise Advisors LLC grew its position in Eli Lilly and Company by 1.8% in the second quarter. Rise Advisors LLC now owns 732 shares of the company's stock worth $571,000 after acquiring an additional 13 shares in the last quarter. Occidental Asset Management LLC increased its stake in shares of Eli Lilly and Company by 0.7% during the 2nd quarter. Occidental Asset Management LLC now owns 1,966 shares of the company's stock worth $1,533,000 after purchasing an additional 13 shares during the last quarter. New Insight Wealth Advisors increased its stake in shares of Eli Lilly and Company by 3.4% during the 2nd quarter. New Insight Wealth Advisors now owns 394 shares of the company's stock worth $307,000 after purchasing an additional 13 shares during the last quarter. Finally, Dash Acquisitions Inc. raised its holdings in shares of Eli Lilly and Company by 2.8% during the 2nd quarter. Dash Acquisitions Inc. now owns 485 shares of the company's stock valued at $387,000 after purchasing an additional 13 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.
Get Eli Lilly and Company alerts:
Analyst Upgrades and Downgrades
A number of equities research analysts recently issued reports on LLY shares. HSBC upped their price objective on shares of Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. Cantor Fitzgerald upped their price target on Eli Lilly and Company from $925.00 to $985.00 and gave the stock an "overweight" rating in a research note on Friday, October 31st. UBS Group raised their price objective on Eli Lilly and Company from $895.00 to $1,080.00 and gave the company a "buy" rating in a research note on Friday, November 7th. Berenberg Bank reaffirmed a "hold" rating and set a $830.00 target price (down previously from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. Finally, Scotiabank assumed coverage on Eli Lilly and Company in a report on Thursday, November 13th. They set a "sector outperform" rating and a $1,165.00 price target on the stock. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and seven have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $1,027.95.
- HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?
Get Our Latest Stock Report on Eli Lilly and Company
Eli Lilly and Company Stock Performance
Shares of NYSE LLY opened at $1,058.05 on Friday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,066.65. The company has a market cap of $1.00 trillion, a P/E ratio of 69.15, a P/E/G ratio of 1.21 and a beta of 0.43. The business's 50 day moving average is $855.89 and its two-hundred day moving average is $787.66. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.
- Down 45% Year-to-Date, Novo Nordisk Ignites a Price War
Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter last year, the company posted $1.18 earnings per share. Eli Lilly and Company's quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.
Eli Lilly and Company Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be issued a dividend of $1.50 per share. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company's payout ratio is presently 29.35%.
About Eli Lilly and Company
(Free Report)Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Recommended Stories
- Five stocks we like better than Eli Lilly and Company
- How is Compound Interest Calculated?
- A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves
- How to Use the MarketBeat Dividend Calculator
- 12 Analysts Just Raised CrowdStrike Targets—Here’s What They See Coming
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Palo Alto Networks Stock Just Pulled Back—Is This a Prime Buy Zone?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Eli Lilly and Company Right Now?
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
